The test showed 90 percent sensitivity and 75 percent specificity in a 250-patient blinded study, even without the addition of clinical risk information.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
Researchers traced genomic, epigenomic, and expression features in lung carcinoma in situ cases that regressed or progressed to invasive lung squamous cell carcinomas.
In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.
The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
Researchers have shown nanoparticles can enrich low molecular weight, low abundance plasma proteins that are hard to detect using standard proteomic workflows.
New research suggests that the physicochemical changes to DNA in a cancer-related methylation landscape can alter a DNA molecule's affinity for gold substrates.
With a DNA methylation atlas and deconvolution algorithm, researchers are attempting to trace cfDNA back to tissue sources in healthy or ill individuals.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
